Global private equity and venture capital news and research

Syndax Pharmaceuticals raises $26.6m Series B round from healthcare VCs

27 Aug 2013

US-based Syndax Pharmaceuticals has secured a $26.6m Series B financing from investors including healthcare-focused venture capital firms Domain Associates, MPM Capital, Forward Ventures and Russia’s RusnanoMedInvest (RMI).

Syndax said it plans to use the proceeds to continue advancement of its late-stage pipeline of epigenetic-based combination therapies for treatment-resistant cancers

“Entinostat represents the most advanced clinical programme of an epigenetic therapy in solid tumors,” said Arlene Morris, Syndax’s chief executive officer. “We have a unique opportunity to help a patient population where safe and effective treatments capable of extending survival are needed desperately. The Series B financing enables us to continue to advance entinostat toward registration, where we believe the opportunity in breast cancer and lung cancer alone exceeds $2 billion.”

RMI is Russia’s and Eastern Europe’s largest venture capital firm specialising in innovative development medicine and pharmaceuticals. It was launched in March 2012 with initial funding – $380m.

Copyright © 2013 AltAssets



Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014